Vir Biotechnology, Inc.
VIR
$10.87
-$0.31-2.77%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 76,685.26% | -102.48% | 504.86% | -89.92% | -110.15% |
| Total Other Revenue | -- | -- | 44.75% | -- | -- |
| Total Revenue | 19,582.54% | -100.96% | 417.78% | -89.92% | -60.52% |
| Cost of Revenue | 38.72% | -6.63% | -14.07% | -22.42% | -7.27% |
| Gross Profit | 207.64% | 4.14% | 73.07% | 21.59% | 5.67% |
| SG&A Expenses | 35.51% | -2.53% | -11.55% | -13.65% | -26.37% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 38.13% | -5.94% | -13.55% | -21.40% | -11.54% |
| Operating Income | 161.95% | 3.86% | 59.07% | 20.65% | 10.40% |
| Income Before Tax | 172.44% | -3.78% | 58.86% | 23.68% | 20.80% |
| Income Tax Expenses | 5.29% | 962.50% | -59.30% | -5.08% | 111.24% |
| Earnings from Continuing Operations | 172.17% | -3.91% | 58.96% | 23.66% | 19.82% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 172.17% | -3.91% | 58.96% | 23.66% | 19.82% |
| EBIT | 161.95% | 3.86% | 59.07% | 20.65% | 10.40% |
| EBITDA | 165.94% | 3.90% | 60.57% | 20.98% | 9.70% |
| EPS Basic | 159.58% | 3.06% | 59.67% | 24.91% | 21.11% |
| Normalized Basic EPS | 162.91% | 6.76% | 61.55% | 19.97% | 7.19% |
| EPS Diluted | 158.65% | 3.06% | 59.67% | 24.91% | 21.11% |
| Normalized Diluted EPS | 162.48% | 6.76% | 61.55% | 19.97% | 7.19% |
| Average Basic Shares Outstanding | 21.14% | 7.19% | 1.77% | 1.67% | 1.63% |
| Average Diluted Shares Outstanding | 21.98% | 7.19% | 1.77% | 1.67% | 1.63% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |